Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

NASDAQ | AVEO (Common Stock)
$2.30 - 0.08
Stock chart for: AVEO.O.  Currently trading at $2.30 with a 52 week high of $4.24 and a 52 week low of $1.86.
08/14/18 3:41 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in ChinaRead More
AVEO Reports Second Quarter 2018 Financial Results and Provides Business UpdateRead More
AVEO Oncology to Present at the Canaccord Genuity 38th Annual Growth ConferenceRead More

Latest Event